Pharmacokinetics of HIV therapies in pregnant patients: an update

References

• Harvey KM Adherence to highly active antiretroviral therapy (HAART) among HIV-infected perinatal clinic attendees and the impact on mother to child (MTCT) transmission of HIV in South East regional health authority (SERHA), Jamaica. 2017.
   Google Scholar
• De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. Jama. 2000;283:1175–1182.
   Google Scholar
• WHO. PMTCT strategic vision: preventing mother-to-child transmission of HIV to reach the UNGASS and millennium development goals 2010.
   Google Scholar
• WHO. HIV/AIDs data and statistics. 2018. Available from: https://www.who.int/hiv/data/en/
   Google Scholar
• WHO. Consolidated guidelines on HIV prevention. diagnosis, treatment and care for key populations; 2017. Geneva, Switzerland: World Health Organization Department of HIV/AIDS.
   Google Scholar
• UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2011.
   Google Scholar
• WHO. WHO validates countries’ elimination of mother-to-child transmission of HIV and syphilis. 2016 [cited 2016 Jun 8]. Available from: https://www.who.int/en/news-room/detail/08-06-2016-who-validates-countries-elimination-of-mother-to-child-transmission-of-hiv-and-syphilis
   Google Scholar
• PAHO W Six Caribbean territories and states eliminate mother-to-child transmission of HIV and syphilis. 2017.
   Google Scholar
• Vrazo AC, Sullivan D, Phelps BR. Eliminating mother-to-child transmission of HIV by 2030: 5 strategies to ensure continued progress. Global Health. 2018;6:249–256.
   Google Scholar
• Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015;61(11):1715–1725.
   Google Scholar
• WHO. Update of recommendations on first- and second-line antiretroviral regimens. 2019.
   Google Scholar
• Costantine M. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65.
   Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics. Clin Pharmacokinet. 2005;44:989–1008.
   Google Scholar
• Roustit M, Jlaiel M, Leclercq P, et al. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66:179–195.
   Google Scholar
• Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics. 2012;13:1501–1522.
   Google Scholar
• Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51:639–659.
   Google Scholar
• Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. BJOG. 1981;88:1–9.
   Google Scholar
• Olagunju A, Bolaji O, Neary M, et al. Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Pharmacogenet Genomics. 2016;26:381–389.
   Google Scholar
• Lamorde M, Wang X, Neary M, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400 mg once daily during pregnancy and post-partum. Clin Infect Dis. 2018;67:785–790.
   Google Scholar
• Gini J, Olagunju A, Dickinson L, et al. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics. 2019;20:217–223.
   Google Scholar
• Focà E, Calcagno A, Bonito A, et al. Pharmacokinetic changes during pregnancy according to genetic variants: a prospective study in HIV-infected patients receiving atazanavir-ritonavir. Antimicrob Agents Chemother. 2018;62:e00309–18.
   Google Scholar
• Aspiroz EL, Figueroa SEC, Gómez AI, et al. CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. Clin Drug Investig. 2015;35:61–66.
   Google Scholar
• Olagunju A. Pharmacogenetics of antiretroviral drugs used for prevention of mother-to-child transmission of HIV during pregnancy and lactation. In: University of liverpool. Pharmacogenomics; 2015. p. 15101–22
   Google Scholar
• Hodel EM, Marzolini C, Waitt C, et al. Pharmacokinetics, placental and breast milk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. Curr Pharm Des. 2019;25:556–576.
   Google Scholar
• Rentsch KM. Drug exposure in newborns: effect of selected drugs prescribed to mothers during pregnancy and lactation. Ther Drug Monit. 2020;42:255–263.
   Google Scholar
• Krubiner CB, Faden RR, Cadigan RJ, et al. Advancing HIV research with pregnant women: navigating challenges and opportunities. AIDS. 2016;30:2261.
   Google Scholar
• Schalkwijk S, Ter Heine R, Colbers AC, et al. A mechanism-based population pharmacokinetic analysis assessing the feasibility of efavirenz dose reduction to 400 mg in pregnant women. Clin Pharmacokinet. 2018;57:1421–1433.
   Google Scholar
• Group ES. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383:1474–1482.
   Google Scholar
• Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379:979–981.
   Google Scholar
• Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32:729–737.
   Google Scholar
• Kenneth Kintu TM, Nakibuka J, Papamichael C, et al. RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: dolPHIN-2. Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington, USA, 2019.
   Google Scholar
• Bornhede R, Soeria-Atmadja S, Westling K, et al. Dolutegravir in pregnancy-effects on HIV-positive women and their infants. Eur J Clin Microbiol Infect Dis. 2018;37:495–500.
   Google Scholar
• Zash R. New studies and WHO guidance clarify the way forward for use of dolutegravir in women of childbearing age. In IAS 2019. 22nd International AIDS conference 2018, Mexico; 2019.
   Google Scholar
• Jeong H, Choi S, Song J, et al. Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008;38:62–75.
   Google Scholar
• DolPHIN-2. Policy brief: the dolPHIN-2 study 2019.
   Google Scholar
• Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med. 2019;16:e1002895.
   Google Scholar
• Mounce ML, Pontiggia L, Adams JL. A single-center retrospective cohort analysis of maternal and infant outcomes in HIV-infected mothers treated with integrase inhibitors during pregnancy. Infect Dis Ther. 2017;6:531–544.
   Google Scholar
• Group NAS. Dolutegravir-based or low-dose efavirenz–based regimen for the treatment of HIV-1. N Engl J Med. 2019;381:816–826.
   Google Scholar
• Venter WD, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803–815.
   Google Scholar
• Bhavadharini B, Anjana RM, Deepa M, et al. Gestational weight gain and pregnancy outcomes in relation to body mass index in Asian Indian women. Indian J Endocrinol Metab. 2017;21:588.
   Google Scholar
• Eliasdottir O, Harðardóttir H, Þórkelsson Þ. The effect of maternal weight on pregnancy outcome. Laeknabladid. 2010;96:691–696.
   Google Scholar
• Boyd SD, Sampson MR, Viswanathan P, et al. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint. Aids. 2019;33:1089–1093.
   Google Scholar
• Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018;32:2507–2516.
   Google Scholar
• Marzolini C, Decosterd L, Winterfeld U, et al. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report. Br J Clin Pharmacol. 2017;83:2835–2838.
   Google Scholar
• Schalkwijk S, Colbers A, Konopnicki D, et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS. 2016;30:807–808.
   Google Scholar
• Crauwels HM, Osiyemi O, Zorrilla C, et al. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen. HIV Med. 2019;20:337–343.
   Google Scholar
• PREZCOBIX [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies. Cited from 2020 Jan 26. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/PREZCOBIX-pi.pdf.
   Google Scholar
• STRIBILD [package insert]. Foster City, CA: gilead Sciences, Inc. Cited from 2020 Jan 26. Available from: https://www.gilead.com/-/media/5b9b2d5ebf6a494a8730dfa627fda606.ashx.
   Google Scholar
• GENVOYA [package insert]. Foster city, CA: gilead Sciences, Inc Cited from 2020 Jan 26. Available from: https://www.gilead.com/-/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf
   Google Scholar
• SYMTUZA [package insert]. Titusville, NJ: janssen Pharmaceutical Companies. Cited from 2020 Jan 26. Available at: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SYMTUZA-pi.pdf
   Google Scholar
• EVOTAC [package insert]. Princeton, NJ: bristol-myers squibb company. Cited from 2020 Jan 26. Available at: https://packageinserts.bms.com/pi/pi_evotaz.pdf
   Google Scholar
• Momper JD, Stek A, Wang J et al. Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum. 20th International workshop on clinical pharmacology of HIV, hepatitis, and other antiviral drugs. Noordwijk, the Netherlands. 14–16 May 2019. Oral abstract 10. Cited from 2020 Jan 27. Available from: http://regist2.virology-education.com/presentations/2019/20AntiviralPK/27_Momper.pdf
   Google Scholar
• Wang P, Shehu AI, Liu K, et al. Biotransformation of Cobicistat: metabolic pathways and enzymes. Drug Metab Lett. 2016;10:111–123.
   Google Scholar
• Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633–639.
   Google Scholar
• Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6:689–699.
   Google Scholar
• Siemieniuk RA, Foroutan F, Mirza R, et al. Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis. BMJ Open. 2017;7:e019022.
   Google Scholar
• Podany AT, Bares SH, Havens J, et al. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. AIDS. 2018;32:761–765.
   Google Scholar
• Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75:211–218.
   Google Scholar
• Angione SA, Cherian SM, Ozdener AE. A review of the efficacy and safety of genvoya(R) (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in the Management of HIV-1 Infection. J Pharm Pract. 2018;31:216–221.
   Google Scholar
• Momper JD, Stek A, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. Presented at: 22nd International AIDS Conference. Amsterdam, Netherlands; 2018.
   Google Scholar
• Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60:316–322.
   Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143–155.
   Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2019;83(3):310–318.
   Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a Trial R. Open Forum Infect Dis. 2019;6:ofz056.
   Google Scholar
• Benaboud S, Treluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 Women. Antimicrob Agents Chemother. 2012;56:776–782.
   Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063–2072.
   Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073–2082.
   Google Scholar
• Mandal S, Prathipati PK, Belshan M, et al. A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study. Antiviral Res. 2019;167:83–88.
   Google Scholar
• Mandal S, Khandalavala K, Pham R, et al. Cellulose acetate phthalate and antiretroviral nanoparticle fabrications for HIV pre-exposure prophylaxis. Polymers. 2017;9:423.
   Google Scholar
• Tatham LM, Savage AC, Dwyer A, et al. Towards a maraviroc long-acting injectable nanoformulation. Eur J Pharm Biopharm. 2019;138:92–98.
   Google Scholar
• Hoeben E, Borghys H, Looszova A, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54:2042–2050.
   Google Scholar
• Spreen W, Ford S, Chen S et al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor S/GSK1265744 long acting parenteral nanosuspension following single dose administration to healthy adults. 19th International AIDS Conference, Washington, DC, USA. p. 22–27.
   Google Scholar
• Kraft JC, McConnachie LA, Koehn J, et al. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS. 2017;31:765.
   Google Scholar
• Shibata A, McMullen E, Pham A, et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses. 2013;29:746–754.
   Google Scholar
• Dr. Dongwei Guo DJH. INJECTABLE NANOMEDICINES – New Developments in Long-Acting Injectable Nanoformulations. Drug development & delivery. Montville; 2018.
   Google Scholar
• Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018;6:e804–e10.
   Google Scholar
• Farrow T, Deaton C, Nguyen N, et al. Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects. In: HIV Glasgow. National AIDS treatment advocacy project conference report reported by Jules Levin; 2018. p. 28–31.
   Google Scholar
• van der Galiën R, Ter Heine R, Greupink R, et al. Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet. 2019;58:309–323.
   Google Scholar
• Mordant C, Schmitt B, Pasquier E, et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem. 2007;42:567–579.
   Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   Google Scholar
• Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–1155.
   Google Scholar
• Fernandez C, van Halsema CL. Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV AIDS (Auckl). 2019;11:179.
   Google Scholar
• Orkin C, Arasteh K, Hernández-Mora MG et al. Long-active cabotegravir+ rilpivirine for HIV maintenance: flair week 48 results. 2019.
   Google Scholar
• Swindells S, Andrade-Villanueva J, Richmond G Long-acting cabotegravir+ rilpivirine as maintenance therapy: ATLAS week 48 results. Conference on Retroviruses and Opportunistic Infections, Seattle Washington, USA.
   Google Scholar
• ViiV Healthcare press statement. ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV (21 December 2019). Cited from 2020 Jan 29. Available from: https://viivhealthcare.com/en-us/us-news/us-articles/2019/complete-response-letter-from-us-fda/
   Google Scholar
• Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487–492.
   Google Scholar
• Gilleece Y, Tariq S, Bamford A, et al. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019;20:S2–S85.
   Google Scholar
• Angela, Colbers SS,D, Konopnicki A, et al. Substantially lower rilpivirine plasma concentrations during pregnancy Conference on retroviruses and opportunistic infections. Boston Massachusetts, 2017.
   Google Scholar
• S-j C, Ning M, Zhang Y, et al. 17β-Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α. Acta Pharm Sin B. 2016;6:504–509.
   Google Scholar
• Usui T, Kuno T, Mizutani T. Induction of human UDP-glucuronosyltransferase 1A1 by cortisol-GR. Mol Biol Rep. 2006;33:91–96.
   Google Scholar
• Kawamoto A, Kodama E, Sarafianos SG, et al. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol. 2008;40:2410–2420.
   Google Scholar
• Ohrui H, Kohgo S, Hayakawa H, et al. 2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against wide spectrum of HIV-1 strains, favorable toxic profiles, and stability in plasma. Nucleosides, Nucleotides, and Nucleic Acids. 2007;26:1543–1546.
   Google Scholar
• Markowitz M, Sarafianos SG. 4ʹ-Ethynyl-2-fluoro-2ʹ-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. Curr Opin HIV AIDS. 2018;13:294–299.
   Google Scholar
• Grobler J, McHale C, Freddo C et al. MK-8591 concentrations at sites of HIV transmission and replication. Conference on Retroviruses and Opportunistic Infections, Seattle Washington, USA. p. 13–16.
   Google Scholar
• Zhang W, Hu M, Shi Y, et al. Vaginal microbicide film combinations of two reverse transcriptase inhibitors, EFdA and CSIC, for the prevention of HIV-1 sexual transmission. Pharm Res. 2015;32:2960–2972.
   Google Scholar
• Matthews RP, Patel SEB,M, Zhu W, et al. First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year. 10th International AIDS Society Conference on HIV Science Mexico City, Mexico; 2019.
   Google Scholar
• Molina YY JM, Saud AA, Bettacchi C, et al. Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naïve adults with HIV-1 infection. 10th International AIDS Society Conference on HIV Science. Mexico City, Mexico; 2019.
   Google Scholar
• Rohan LC Long acting film technology for contraception and HIV prevention (LATCH). Magee-Women’s Research Institute and Foundation: National Institute of Health (NIH), 2019.
   Google Scholar
• Zhou CC, Ahmad S, Mi T, et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007;100:88–95.
   Google Scholar
• Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. Clin Infect Dis. 2019;68:535–544.
   Google Scholar
• Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241–2247.
   Google Scholar
• Bleasby K, Fillgrove KL, Houle R, et al. In vitro evaluation of the drug interaction potential of doravirine. In: Antimicrob agents chemother, American society for microbiology. 2019. p. 63.
   Google Scholar
• Merck Sharp & Dohme Corp. Islatravir (MK-8591) with doravirine and lamivudine in participants infected with human immunodeficiency virus type 1 (MK-8591-011) (DRIVE2Simplify). Cited from 2020 Jan 29. Available from: https://clinicaltrials.gov/ct2/show/NCT03272347
   Google Scholar
• Molina J, Yazdanpanah Y, Saud AA et al. Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naïve adults with HIV-1 infection. IAS 2019. Mexico City, 2019.
   Google Scholar
• Merck Sharp & Dohme Corp. Randomized, double-blind, efficacy, and safety study of doravirine/islatravir (dor/isl) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) Infection (MK-8591A-020). Cited from 2020 Jan 29. Available from: https://clinicaltrials.gov/ct2/show/NCT04233879
   Google Scholar
• Molina J, Yazdanpanah Y, Saud AA et al. MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naïve adults with HIV-1 infection. IAS 2019. Mexico City, 2019.
   Google Scholar
• Boyle A, Moss CE, Marzolini C, et al. Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet. 2019;58:1553–1565.
   Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
   Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–2143.
   Google Scholar
• Noguchi LM, Hoesley C, Kelly C, et al. Pharmacokinetics of dapivirine transfer into blood plasma, breast milk, and cervicovaginal fluid of lactating women using the dapivirine vaginal ring. Antimicrob Agents Chemother. 2019;63:e01930–18.
   Google Scholar
• Network MT, numbers g. phase 3b, randomized, open-label, safety, and drug detection study of dapivirine vaginal ring and oral TRUVADA® in breastfeeding mother-infant Pairs. 2019.
   Google Scholar
• Makanani B, Balkus JE, Jiao Y, et al. Pregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancy. J Acquir Immune Defic Syndr. 2018;79:566–572.
   Google Scholar
• To EE, Hendrix CW, Bumpus NN. Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues. Biochem Pharmacol. 2013;86:979–990.
   Google Scholar
• Ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 2004;71:41–54.
   Google Scholar
• González R, Rupérez M, Sevene E, et al. Effects of HIV infection on maternal and neonatal health in southern mozambique: A prospective cohort study after a decade of antiretroviral drugs roll out. PloS One. 2017;12:e0178134.
   Google Scholar
• Eki-Udoko FE, Sadoh AE, Ibadin MO, et al. Prevalence of congenital malaria in newborns of mothers co-infected with HIV and malaria in Benin city. Infect Dis (Auckl). 2017;49:609–616.
   Google Scholar
• C Mm T, Dorrucci M, Naha N, et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquired Immune Deficiency Syndromes. 2003;1:284–294.
   Google Scholar
• Desai M, Ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.
   Google Scholar
• Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67:2213–2221.
   Google Scholar
• Maganda BA, Ngaimisi E, Kamuhabwa AA, et al. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J. 2015;14:179.
   Google Scholar
• Ba Mo M, Ngaimisi E, Kamuhabwa AA, et al. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenomics J. 2016;16:88–95.
   Google Scholar
• Adegbola A, Abutaima R, Olagunju A, et al. Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria coinfection. Antimicrob Agents Chemother. 2018;62:e01252–18.
   Google Scholar
• Dickmann LJ, Isoherranen N. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metab Dispos. 2013;41:270–274.
   Google Scholar
• Kajubi R, Huang L, Jagannathan P, et al. Antiretroviral therapy with efavirenz accentuates pregnancy‐associated reduction of dihydroartemisinin‐piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther. 2017;102:520–528.
   Google Scholar
• Wallender E, Vucicevic K, Jagannathan P, et al. Predicting optimal dihydroartemisinin-piperaquine regimens to prevent malaria during pregnancy for HIV-infected women receiving efavirenz. J Infect Dis. 2017;17(6):964–972.
   Google Scholar
• Haaland RE, Otieno K, Martin A, et al. Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy. AIDS Res Hum Retroviruses. 2018;34:912–915.
   Google Scholar
• Walimbwa SI, Lamorde M, Waitt C, et al. Drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine. Antimicrob Agents Chemother. 2019;63:e01310–18.
   Google Scholar
• Worley H Intersecting epidemics: tuberculosis and HIV. 2006.
   Google Scholar
• Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis. 1998;2:96–104.
   Google Scholar
• Bates M, Ahmed Y, Kapata N, et al. Perspectives on tuberculosis in pregnancy. Inter J Infect Dis. 2015;32:124–127.
   Google Scholar
• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global Burden of Disease Study. Lancet. 1997;349:1269–1276.
   Google Scholar
• Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55:1532–1549.
   Google Scholar
• Dooley KE, Charles F, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948–961.
   Google Scholar
• Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2014;211:197–205.
   Google Scholar
• Rajoli RK, Curley P, Chiong J, et al. Predicting drug–drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis. 2018;219:1735–1742.
   Google Scholar
• Benhammou V, Tubiana R, Matheron S, et al. HBV or HCV coinfection in HIV-1-infected pregnant women in France: prevalence and pregnancy outcomes. J Acquir Immune Defic Syndr. 2018;77:439–450.
   Google Scholar
• Freriksen JJ, van Seyen M, Judd A, et al. direct‐acting antivirals for the treatment of HCV during pregnancy and lactation‐implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment Pharmacol Ther. 2019;50:738–750.
   Google Scholar
• Chappell C, Kirby B, Scarsi K, et al. A pharmacokinetic and treatment study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus. Am J Clin Exp Obstet Gynecol. 2019;221:666.
   Google Scholar
• UNAIDS. Women and HIV: a spotlight on adolescent girls and young women. In: UNAIDS. Geneva, Switzerland: UNAIDS; 2019.
   Google Scholar
• Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071–1087.
   Google Scholar
• Drake AL, Wagner A, Richardson B, et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001608.
   Google Scholar
• Papworth E, Schwartz S, Ky-Zerbo O, et al. Mothers who sell sex: a potential paradigm for integrated HIV, sexual, and reproductive health interventions among women at high risk of HIV in Burkina Faso. J Acquir Immune Defic Syndr. 2015;68:S154–S61.
   Google Scholar
• Mhlanga FG, Noguchi L, Balkus JE, et al. Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials. 2018;19:8–14.
   Google Scholar
• Musekiwa A, Muchiri E, Manda SO, et al. Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis. PloS One. 2013;8:e77014.
   Google Scholar
• Alsmadi MM, Idkaidek N. Optimization of drugs pharmacotherapy during pregnancy using physiologically based pharmacokinetic models - an update. Curr Drug Metab. 2018;19:972–978.
   Google Scholar
• Ke AB, Greupink R, Abduljalil K. Drug dosing in pregnant women: challenges and opportunities in using physiologically based pharmacokinetic modeling and simulations. CPT Pharmacometrics Syst Pharmacol. 2018;7:103–110.
   Google Scholar
• De Sousa Mendes M, Hirt D, Urien S, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015. 10.1111/bcp.12685.
   Google Scholar
• Colbers A, Greupink R, Litjens C, et al. Physiologically based modelling of darunavir/ritonavir pharmacokinetics during pregnancy. Clin Pharmacokinet. 2016;55:381–396.
   Google Scholar
• Gockenbach M Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy (oral abstract 16). 20th International workshop on clinical pharmacology of HIV, hepatitis, and other antiviral drugs. Noordwijk, the Netherlands. 14–16 May 2019. Cited from 2020 Feb 03. Available from: http://regist2.virology-education.com/presentations/2019/20AntiviralPK/33_Gockenbach.pdf
   Google Scholar
• Roberts O, Rajoli RKR, Back DJ, et al. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. J Antimicrob Chemother. 2018;73:1004–1012.
   Google Scholar
• Zhang Z, Unadkat JD. Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs. Drug Metab Dispos. 2017;45:939–946.
   Google Scholar
• Zhang Z, Imperial MZ, Patilea-Vrana GI, et al. Development of a novel maternal-fetal physiologically based pharmacokinetic model i: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses. Drug Metab Dispos. 2017;45:920–938.
   Google Scholar
• Liu XI, Momper JD, Rakhmanina N, et al. Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol. 2019;60(2):240–255.
   Google Scholar
• Atoyebi SA, Rajoli RKR, Adejuyigbe E, et al. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: thalidomide versus efavirenz as case studies. Eur J Pharm Sci. 2019;140:105068.
   Google Scholar
• US Food and Drug Administration (2018). Physiologically based pharmacokinetic analyses - format and content. Cited from 2020 February 03. Available from: https://www.fda.gov/media/101469/download
   Google Scholar
• le Roux SM, Abrams EJ. Efavirenz in pregnancy. Lancet HIV. 2020;7:e6–e8.
   Google Scholar
• Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. Aids. 2003;17:1769–1785.
   Google Scholar
• Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008;61:8–12.
   Google Scholar
• Morén C, Noguera-Julián A, Garrabou G, et al. Mitochondrial disturbances in HIV pregnancies. Aids. 2015;29:5–12.
   Google Scholar
• García-Otero L, López M, Guitart-Mampel M, et al. Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment. PloS one. 2019; 14.
   Google Scholar
• Williams PL, Yildirim C, Chadwick EG, et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV. 2020;7:e49–e58.
   Google Scholar
• Crowell CS, Williams P, Yildirim C et al. LB5. safety of in utero antiretroviral (ARV) exposure: neurologic outcomes in HIV-exposed, uninfected children. Open Forum Infectious Diseases.. Oxford University Press. 2018;5(1):S761
   Google Scholar
• Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. Aids. 2014;28:S123–S31.
   Google Scholar